03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
20:31 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal; nephropathy; renal damage Mouse studies suggest FNDC5 or promoting PGC-1α expression could help treat nephropathy, chronic kidney disease (CKD) and kidney damage. In a mouse model of chemical-induced nephropathy, FNDC5 or skeletal muscle-specific overexpression...
18:11 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Cell culture and mouse experiments identified oxyindole-based inhibitors of PGC-1α gluconeogenic activity that could help treat Type II diabetes. High throughput screening of a small molecule library in in vitro and cell-based assays identified...
07:00 , Nov 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest promoting ID2 expression or inhibiting TCF4 could help treat PGC-1α-deficient metastatic melanoma. In primary tumor samples from 68 melanoma patients, invasive tumor pathology was associated with low levels...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α, to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While the findings...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1-α (PPARGC1A; PGC-1a)

Cancer INDICATION: Melanoma; viral infection Mouse studies suggest enhancing PPARGC1A activity in T cells could help treat melanoma and chronic viral infections. In a mouse model of melanoma, adoptive transfer of tumor-targeting T cells induced to express...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1α (PPARGC1A; PGC-1α)

Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest promoting PPARGC1A expression could help treat metastatic prostate cancer. In prostate cancer patients, PPARGC1A levels were lower in primary tumor samples than in normal prostate...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1α (PPARGC1A; PGC-1α); nicotinamide adenine dinucleotide (NAD+)

Renal disease INDICATION: Renal damage Mouse studies suggest promoting PPARGC1A expression or the NAD+ precursor nicotinamide could help treat acute kidney injury (AKI). In a mouse model of renal ischemia, overexpression of PPARGC1A in the kidneys decreased...
08:00 , Feb 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1-α (PPARGC1A; PGC-1α)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest promoting PPARGC1A expression could help treat breast cancer. In human breast cancer cell lines, a tool compound that promoted PPARGC1A expression decreased proliferation compared with vehicle. In...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor (PPAR) γ coactivator 1-α (PPARGC1A; PGC-1α)

Cardiovascular disease INDICATION: Atherosclerosis Studies in mice suggest PPARGC1A or the PPARGC1A activator α-lipoic acid could help treat or prevent atherosclerosis. In a mouse model of atherosclerosis, overexpression of PPARGC1A or treatment with α-lipoic acid increased aortic...